![](jpg/gettyimages-1280895783-150x150.jpg)
Diagnostics
-
Sema4 secures a deal to acquire GeneDx, capturing $200M in private investment
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company’s goal of translating insights from genomics data and analytics into making precision medicine a standard of care.
-
MedCity Influencers, Diagnostics
To reduce heart attack rates, make CCTA the new standard of care
To improve heart attack prevention, there is an urgent unmet need to modernize our approach from late-stage symptom-driven care to direct disease-based care, a care paradigm that addresses heart attack risk in all patients across the entire continuum of heart disease severity.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Investor insights: Ling Wong of Sea Lane Ventures and Lightspeed Venture Partners
What draws investors to healthcare startups? In this series in the runup to MedCity INVEST in Chicago, we’ll highlight these perspectives. If you’re a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
-
As genetic testing expands, evidence and awareness needed to spur adoption
Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of Color explained what they think needs to happen to make these tests accessible and affordable for more people.
-
INVEST Pitch Perfect Winner Spotlight: Oncoustics taps ultrasound data to detect liver disease
The Toronto-based startup is applying AI to ultrasound signals. It differentiates healthy tissue from diseased tissue by measuring its acoustic properties.
-
A preview of MedCity INVEST 2022: A return to in-person conferences
INVEST, scheduled for March 28-30, 2022 in Chicago, marks a return to in-person events for MedCity News. The conference, held in partnership with Mid-America Healthcare Investors Network, will spotlight healthcare innovation, investment trends, and share insights from healthcare executives.
-
MedCity Influencers, BioPharma, Diagnostics
How spatial transcriptomics will map the next frontier in biology
Recognized as Method of the Year by Nature in 2020, spatial transcriptomics employs advanced imaging methods with novel chemistry techniques that stand to dramatically expand our understanding of health and disease.
-
Devices & Diagnostics, Diagnostics
GE plans to spin out healthcare business in 2023
General Electric plans to spin out its healthcare business into a publicly traded entity in 2023. It’s part of a broader restructuring as the company looks to turn around its business.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Ellume recalls 2.2M home tests due to risk of false positives
The company expanded a recall of its at-home Covid-19 tests due to a manufacturing error. The FDA upped the recall to a Class 1 recall, its most serious level, after noting a higher-than-acceptable false positive rate for the affected tests.
-
Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.
-
MedCity Influencers, BioPharma, Diagnostics
Declining vaccine antibody levels require more dynamic immunity assessments
New semiquantitative tests offer a more granular understanding of our protective immunity, not only identifying Covid-19 antibodies but providing direct, individualized measures of neutralizing antibody levels.
-
MedCity Influencers, Diagnostics
Sepsis: Treating a global health crisis at the point of care
Utilizing POC testing for sepsis is a pragmatic solution for risk-stratification of new patients, helping physicians to prioritize those for treatment based on the severity of their condition.
-
BioPharma, Devices & Diagnostics, Diagnostics, Health IT, Payers, Pharma, SYN
How your healthcare business can generate more leads
A new service from MedCity News is designed to add momentum to lead generation campaigns.
-
FDA authorizes Labcorp’s at-home test kit for Covid-19, flu
The Food and Drug Administration granted an emergency use authorization for an at-home Covid-19 and flu test kit by Labcorp. It uses a test that was developed by Roche and authorized last year.